Research Topics
| Phillip ScheinbergSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemiaPhillip Scheinberg
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Br J Haematol 133:622-7. 2006..In our study, the response rate in refractory patients was inferior to what has been previously reported...- Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: implications for graft engineeringPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1202, USA
Exp Hematol 34:788-95. 2006..To better understand the alloresponse between HLA-identical related pairs, we characterized the alloreactive T cells generated in a mixed lymphocyte reaction (MLR) assay system... - Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetilPhillip Scheinberg
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Br J Haematol 133:606-11. 2006..Over half of the relapses occurred during MMF administration. Despite a strong theoretical rationale for its use, MMF did not result in the improvement of response or relapse rates when compared with historical standard h-ATG/CsA... 
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemiaPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
Blood 109:3219-24. 2007....- The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donorPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Blood 114:5071-80. 2009.... - Alloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cellsJ Joseph Melenhorst
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Biol Blood Marrow Transplant 17:800-9. 2011.... - Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized studyPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Haematologica 94:348-54. 2009.... - Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Blood 119:345-54. 2012..We conclude that alemtuzumab is effective in SAA, but best results are obtained in the relapsed and refractory settings. The present trials were registered at www.clinicaltrials.gov as NCT00195624, NCT00260689, and NCT00065260... - T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyElaine M Sloand
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 117:2691-9. 2011..Thus, our results suggest that WT1 is one of the antigens that triggers T cell-mediated myelosuppression in MDS... - High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrowJ Joseph Melenhorst
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 113:2238-44. 2009..These data suggest that concomitant examination of bone marrow specimens in patients with myeloid leukemias might yield more definitive information in the search for immunologic prognosticators of clinical outcome... - Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumabElaine M Sloand
National Heart Lung and Blood Instititute, NIH, Bethesda, MD 20892, USA
Haematologica 95:382-7. 2010.... - Granulocyte transfusions in severe aplastic anemia: an eleven-year experienceKaren Quillen
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
Haematologica 94:1661-8. 2009..Infections, particularly those caused by invasive fungi, are a major cause of death in patients with severe aplastic anemia. The purpose of this study was to analyze our experience with granulocyte transfusions in such patients... - Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissionsElaine M Sloand
Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10 CRC 4 5230, Bethesda, MD 20892, USA
J Clin Oncol 28:5166-73. 2010..Because of the toxicities associated with h-ATG/CsA, we investigated an alternative regimen with alemtuzumab in MDS... 
Horse versus rabbit antithymocyte globulin in acquired aplastic anemiaPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
N Engl J Med 365:430-8. 2011..Although horse ATG is the standard therapy, rabbit ATG is more potent in depleting peripheral-blood lymphocytes and is preferred in other clinical circumstances...- Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporinePhillip Scheinberg
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, 20892 1202, USA
Haematologica 95:1075-80. 2010..Flow cytometry has allowed for sensitive and precise measurement of glycosylphosphatidylinositol-anchor protein-deficient red blood cells and neutrophils in severe aplastic anemia... - Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramersPratip K Chattopadhyay
Immunotechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Cytometry A 73:1001-9. 2008.... - Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporinePhillip Scheinberg
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
J Pediatr 153:814-9. 2008.... - Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemiaPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, 10 Center Dr, Bldg 10 CRC, Room 3 5140, MSC 1202, Bethesda, MD 20892 1202, USA
JAMA 304:1358-64. 2010..Variations in telomere length have been reported in severe aplastic anemia but their clinical significance is unknown... - Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.NaMatthew J Olnes
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Leuk Res 36:982-9. 2012..Knockdown" of cyclin D1 by RNA interference decreased trisomy 8 cell growth, suggesting that this might be a therapeutic target in MDS... - Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patientsElaine M Sloand
National Heart Lung and Blood Institute, Hematology Branch, Office of Biostatistics Research, Division of Prevention and Population Sciences, National Institutes of Health, Bethesda, MD 20892 1260, USA
Exp Hematol 36:1616-24. 2008..We hypothesized that suPAR, prevents the interaction of urokinase with membrane-anchored uPAR on residual normal cells... - Predicting response to immunosuppressive therapy and survival in severe aplastic anaemiaPhillip Scheinberg
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
Br J Haematol 144:206-16. 2009..In the era of IST, the baseline ARC and ALC together serve as a simple predictor of response following IST, which should guide in risk stratification among patients with SAA... - Aplastic anemiaNeal S Young
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
Curr Opin Hematol 15:162-8. 2008.... - Th17 immune responses contribute to the pathophysiology of aplastic anemiaRegis Peffault De Latour
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Blood 116:4175-84. 2010..01) and more Treg cells (P < .05) at day 10 after lymph node infusion. Th17 immune responses contribute to AA pathophysiology, especially at the early stage during disease progression... - The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangementsPhillip Scheinberg
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol Methods 321:107-20. 2007..Clonotypes shared between the CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- subsets were observed in all 3 UCB and in one adult PBMCs, suggesting that naïve and memory CD4+ T(R) can share the same clonotypes as CD4+ non-T(R) in humans... - Eltrombopag and improved hematopoiesis in refractory aplastic anemiaMatthew J Olnes
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
N Engl J Med 367:11-9. 2012..Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells... - Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromesXingmin Feng
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
Haematologica 96:602-6. 2011..Future studies focusing on cytokines that better discriminate these two entities such as thrombopoietin and chemokine (C-C motif) ligand 3 may be useful tools in clinical practice... - Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decadesJessica M Valdez
Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
Clin Infect Dis 52:726-35. 2011..However, little is known about the current patterns of infections and the impact of advances in anti-infective therapy on survival in SAA... - Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patientsElaine M Sloand
Hematology Branch, National Heart, Lung, and Blood Institute, and the Mark O Hatfield Clinical Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
Transfusion 47:1250-3. 2007..Even patients who have clinically recovered from aplastic anemia have diminished hematopoietic progenitor cells, so the practicability of PBPC mobilization in these individuals is unknown... - Current concepts in the pathophysiology and treatment of aplastic anemiaNeal S Young
Hematology Branch, National Heart, Lung, and Blood Institute NIH, 10 Center Drive, Bldg 10 CRC, Rm 3E 5140, Bethesda, MD 20892 1202, USA
Blood 108:2509-19. 2006..Recent results with alternative sources of stem cells and a variety of conditioning regimens to achieve their engraftment have been promising, with survival in small pediatric case series rivaling conventional transplantation results... - Severe menorrhagia associated with thrombocytopeniaEric D Levens
Reproductive Endocrinology and Infertility, National Institutes of Health, Walter Reed Army Medical Center, National Naval Medical Center, Uniformed Services University of the Health Sciences, Maryland, USA
Obstet Gynecol 110:913-7. 2007 - How I treat acquired aplastic anemiaPhillip Scheinberg
Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
Blood 120:1185-96. 2012.... - Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab)Elaine M Sloand
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Ann Intern Med 144:181-5. 2006..Most patients respond to some form of immunosuppressive treatment, but few prospective clinical trials have been performed... - Infections in patients with aplastic anemiaJessica M Valdez
Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD, USA
Semin Hematol 46:269-76. 2009..The specific immune impairment and current treatment parameters for each of these classes of infection will also be discussed... - Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramersJ Joseph Melenhorst
Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol Methods 338:31-9. 2008.... - Apparent hemolysis following intravenous antithymocyte globulin treatment in a patient with marrow failure and a paroxysmal nocturnal hemoglobinuria cloneMinh Ha Tran
Mark O Hatfield Clinical Research Center, Warren G Magnuson Clinical Center, Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA
Transfusion 46:1244-7. 2006..We report a case of apparent ATG-related hemolysis in a patient with aplastic anemia and a paroxysmal nocturnal hemoglobinuria (PNH) clone... - Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasisMichail S Lionakis
Clinical Mycology Unit, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
PLoS Pathog 8:e1002865. 2012..Thus, neutrophil Ccr1 amplifies late renal immunopathology and increases mortality in invasive candidiasis by mediating excessive recruitment of neutrophils from the blood to the target organ... - Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactionsJennifer Daniel-Johnson
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, and the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
Transfusion 49:1845-9. 2009..Reported cases have involved group O donors. Two cases of PLT-mediated HTRs associated with the same group A plateletpheresis component, collected from a donor taking high doses of probiotics are reported... - Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infectionsJason M Brenchley
Human Immunology Section, Vaccine Research Center VRC, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD, USA
Blood 112:2826-35. 2008..Finally, these data may help account for the nonprogressive nature of nonpathogenic SIV infection in sooty mangabeys... - Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populationsNatalie E R Beveridge
Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Eur J Immunol 37:3089-100. 2007..Overall, these data strongly support the use of MVA85A in humans as a boosting agent to expand polyfunctional M.tb-specific CD4(+) T cells capable of significant secondary responses...